Travelan is made using bovine colostrum from dairy cows which are immunised with a vaccine to produce high levels of enterotoxigenic E coli antibodies. Travelan works by binding to E coli bacteria and effectively prohibiting it from attaching to the intestinal tract and causing travellers’ diarrhoea. The specific antibodies bind to all the E coli serotypes and are not absorbed into the blood. Evedential proof of the tablets’ ability to reduce the risk of travellers diarrhoea is found in recent randomised, double blind placebo trials conducted in Europe and the US. The trials found that Travelan demonstrated protection of up to 90% aginst E coli infection. The trials also found Travelan had no reported side effects and that it also reduced the symptoms of gastrointestinal disorders such as abdominal cramps and stomach pain.
RRP: $22.95 Stockist: www.travelan.com.au.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jun 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jun 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.